產(chǎn)品屬性：
產(chǎn)品名稱(chēng) | Fraxin;Fraxoside; Paviin |
規(guī)格 | 20mg |
貨號(hào) | EY-01Y19719 |
Cas No.: 524-30-1
別名: Fraxetol 8-glucoside; Fraxoside
化學(xué)名: 7-hydroxy-6-methoxy-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
分子式: C16H18O10
分子量: 370.31
溶解度: ≥ 37mg/mL in DMSO
儲(chǔ)存條件: 4°C, protect from light
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Fraxin isolated from Acer tegmentosum, F. ornus or A. hippocastanum, is a glucoside of fraxetin and reported to exert potent anti-oxidative stress action[1], anti-inflammatory and antimetastatic properties. Fraxin shows its antioxidative effect through inhibition of cyclo AMP phosphodiesterase enzyme[2].Fraxin (100 μM) is non-cytotoxic on Hep G2 cells. Fraxin at non-cytotoxic concentrations significantly decreases the t-BHP-induced ROS generation in a dose-dependent manner[1].Fraxin (0.5 mM) shows free radical scavenging effect at high concentration and cell protective effect against H2O2-mediated oxidative stress[2].Fraxin (50 mg/kg, p.o.) significantly blocks the CCl4-induced elevation of ALT and AST. Fraxin (10 and 50 mg/kg, p.o.) significantly reduces the GSSG levels (1.7±0.3 and 1.5±0.2 nM/g liver, respectively) compared with the GSSG levels of the CCl4-treated group[1].
特別提醒公司產(chǎn)品僅供科研使用
